Molecular testing in thyroid cancer: Braf mutation status and mortality
A partir de données portant sur 1 849 patients atteints d'un cancer papillaire de la thyroïde traité entre 1978 et 2011 (âge : 34 à 58 ans ; 438 hommes ; durée médiane de suivi : 33 mois), cette étude multicentrique internationale évalue l'association entre des mutations du gène BRAF V600E et la mortalité spécifique
Thyroid cancer is the ninth most common cancer in the United States, with an incidence that has been increasing sharply since the mid-1990s.1- 2 The majority of thyroid cancers are papillary thyroid cancers (PTC), which arise from thyroid follicular cells. Papillary thyroid tumors grow slowly and often retain sufficient characteristics of thyroid follicular cells to take up iodine, allowing for treatment with radioiodine to ablate residual thyroid cancer cells in cases requiring additional therapy beyond surgery. Papillary thyroid cancer has an excellent prognosis, with 5-year survival rates of 98%.3 However, for the 7% of individuals with aggressive PTC, the natural history is unpredictable and additional therapeutic options are limited.
JAMA , éditorial, 2012